Study of IVB103 injection for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have active wet AMD in one eye (called the study eye), with certain lesion size limits.
- Your vision in the study eye is between 20/63 and 20/400 on a vision chart.
- You have had at least 2 anti-VEGF injections in the study eye in the last 6 months and responded to a standard treatment (aflibercept) during the lead-in period.
- You are not pregnant and agree to use effective birth control during the study and for 12 months after the last dose.
- You do not have other serious eye diseases, uncontrolled health conditions, or recent blood clotting or bleeding issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
Hear when a new nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.